Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc.

Biotechnology • Healthcare • Boston, MA, United States • FNCH (PNK)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

617 229 6499 75 State Street, Boston, MA 02109, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

What Makes Finch Therapeutics (FNCH) a Worthy Investment? - Yahoo Finance
Yahoo Finance • Dec 11
Finch Therapeutics: Post-Trial Decision Can Potentially Drive Shares To Trade Higher - Seeking Alpha
Seeking Alpha • Feb 6
Finch Therapeutics Group to Delist from Nasdaq - Nasdaq
Nasdaq • Oct 21
Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewswire
GlobeNewswire • Oct 21
Finch Therapeutics to delist from Nasdaq by end of October - Investing.com
Investing.com • Oct 21

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Finch Therapeutics Group, Inc. had layoffs?
No layoff events have been recorded for Finch Therapeutics Group, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Finch Therapeutics Group, Inc. have?
Finch Therapeutics Group, Inc. has approximately 1 employees.
What industry is Finch Therapeutics Group, Inc. in?
Finch Therapeutics Group, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Finch Therapeutics Group, Inc. a publicly traded company?
Yes, Finch Therapeutics Group, Inc. is publicly traded under the ticker symbol FNCH on the PNK. The company has a market capitalization of approximately $0.02 billion.
Where is Finch Therapeutics Group, Inc. headquartered?
Finch Therapeutics Group, Inc. is headquartered in Boston, MA, United States at 75 State Street, Boston, MA 02109, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.